Correction to: The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer (International Journal of Clinical Oncology, (2021), 26, 11, (2123-2129), 10.1007/s10147-021-01996-8)

Masayuki Sekine; Takayuki Enomoto; Yoh Watanabe; Hidetaka Katabuchi; Nobuo Yaegashi; Daisuke Aoki

doi:10.1007/s10147-021-02018-3

Correction to: The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer (International Journal of Clinical Oncology, (2021), 26, 11, (2123-2129), 10.1007/s10147-021-01996-8)

Masayuki Sekine, Takayuki Enomoto, Yoh Watanabe, Hidetaka Katabuchi, Nobuo Yaegashi, Daisuke Aoki

Department of Obstetrics and Gynecology (Gynecology)

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

The article The efficacy and safety profile of 2‑weekly dosing of bevacizumab‑containing chemotherapy for platinum‑resistant recurrent ovarian cancer, written by Masayuki Sekine, Takayuki Enomoto, Yoh Watanabe, Hidetaka Katabuchi, Nobuo Yaegashi and Daisuke Aoki was originally published Online First without Open Access.

Original language	English
Pages (from-to)	2130
Number of pages	1
Journal	International Journal of Clinical Oncology
Volume	26
Issue number	11
DOIs	https://doi.org/10.1007/s10147-021-02018-3
Publication status	Published - 2021 Nov

ASJC Scopus subject areas

Surgery
Hematology
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s10147-021-02018-3

Fingerprint

Dive into the research topics of 'Correction to: The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer (International Journal of Clinical Oncology, (2021), 26, 11, (2123-2129), 10.1007/s10147-021-01996-8)'. Together they form a unique fingerprint.

Cite this

Sekine, M., Enomoto, T., Watanabe, Y., Katabuchi, H., Yaegashi, N., & Aoki, D. (2021). Correction to: The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer (International Journal of Clinical Oncology, (2021), 26, 11, (2123-2129), 10.1007/s10147-021-01996-8). International Journal of Clinical Oncology, 26(11), 2130. https://doi.org/10.1007/s10147-021-02018-3

Correction to: The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer (International Journal of Clinical Oncology, (2021), 26, 11, (2123-2129), 10.1007/s10147-021-01996-8). / Sekine, Masayuki; Enomoto, Takayuki; Watanabe, Yoh et al.
In: International Journal of Clinical Oncology, Vol. 26, No. 11, 11.2021, p. 2130.

Research output: Contribution to journal › Comment/debate › peer-review

Sekine, M, Enomoto, T, Watanabe, Y, Katabuchi, H, Yaegashi, N & Aoki, D 2021, 'Correction to: The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer (International Journal of Clinical Oncology, (2021), 26, 11, (2123-2129), 10.1007/s10147-021-01996-8)', International Journal of Clinical Oncology, vol. 26, no. 11, pp. 2130. https://doi.org/10.1007/s10147-021-02018-3

Sekine M, Enomoto T, Watanabe Y, Katabuchi H, Yaegashi N, Aoki D. Correction to: The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer (International Journal of Clinical Oncology, (2021), 26, 11, (2123-2129), 10.1007/s10147-021-01996-8). International Journal of Clinical Oncology. 2021 Nov;26(11):2130. doi: 10.1007/s10147-021-02018-3

Sekine, Masayuki ; Enomoto, Takayuki ; Watanabe, Yoh et al. / Correction to : The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer (International Journal of Clinical Oncology, (2021), 26, 11, (2123-2129), 10.1007/s10147-021-01996-8). In: International Journal of Clinical Oncology. 2021 ; Vol. 26, No. 11. pp. 2130.

@article{52a332a652da473d8f4d3e5273ce51e4,

title = "Correction to: The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer (International Journal of Clinical Oncology, (2021), 26, 11, (2123-2129), 10.1007/s10147-021-01996-8)",

abstract = "The article The efficacy and safety profile of 2‑weekly dosing of bevacizumab‑containing chemotherapy for platinum‑resistant recurrent ovarian cancer, written by Masayuki Sekine, Takayuki Enomoto, Yoh Watanabe, Hidetaka Katabuchi, Nobuo Yaegashi and Daisuke Aoki was originally published Online First without Open Access.",

author = "Masayuki Sekine and Takayuki Enomoto and Yoh Watanabe and Hidetaka Katabuchi and Nobuo Yaegashi and Daisuke Aoki",

note = "Publisher Copyright: {\textcopyright} 2021, The Author(s).",

year = "2021",

month = nov,

doi = "10.1007/s10147-021-02018-3",

language = "English",

volume = "26",

pages = "2130",

journal = "International Journal of Clinical Oncology",

issn = "1341-9625",

publisher = "Springer Japan",

number = "11",

}

TY - JOUR

T1 - Correction to

T2 - The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer (International Journal of Clinical Oncology, (2021), 26, 11, (2123-2129), 10.1007/s10147-021-01996-8)

AU - Sekine, Masayuki

AU - Enomoto, Takayuki

AU - Watanabe, Yoh

AU - Katabuchi, Hidetaka

AU - Yaegashi, Nobuo

AU - Aoki, Daisuke

PY - 2021/11

Y1 - 2021/11

N2 - The article The efficacy and safety profile of 2‑weekly dosing of bevacizumab‑containing chemotherapy for platinum‑resistant recurrent ovarian cancer, written by Masayuki Sekine, Takayuki Enomoto, Yoh Watanabe, Hidetaka Katabuchi, Nobuo Yaegashi and Daisuke Aoki was originally published Online First without Open Access.

AB - The article The efficacy and safety profile of 2‑weekly dosing of bevacizumab‑containing chemotherapy for platinum‑resistant recurrent ovarian cancer, written by Masayuki Sekine, Takayuki Enomoto, Yoh Watanabe, Hidetaka Katabuchi, Nobuo Yaegashi and Daisuke Aoki was originally published Online First without Open Access.

UR - http://www.scopus.com/inward/record.url?scp=85114623668&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85114623668&partnerID=8YFLogxK

U2 - 10.1007/s10147-021-02018-3

DO - 10.1007/s10147-021-02018-3

M3 - Comment/debate

C2 - 34499262

AN - SCOPUS:85114623668

SN - 1341-9625

VL - 26

SP - 2130

JO - International Journal of Clinical Oncology

JF - International Journal of Clinical Oncology

IS - 11

ER -

Correction to: The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer (International Journal of Clinical Oncology, (2021), 26, 11, (2123-2129), 10.1007/s10147-021-01996-8)

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this